Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002259 · ClinicalTrials.gov registry record · Phase 2

Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma

A Phase 2 study, sponsored by Lederle Laboratories.

Completed
Registry status
Phase 2
Development phase

NCT00002259: Completed Phase 2 study, sponsored by Lederle Laboratories.

NCT00002259 is a Phase 2 study that has completed, run by Lederle Laboratories. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002259, a Phase 2 study, has completed, sponsored by Lederle Laboratories.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.

Interventions

  • DRUG Mitoxantrone hydrochloride

Trial Details

FieldValue
Phase Phase 2

Sponsor

Lederle Laboratories

6 total trials

What the Registry Record Tells You About NCT00002259

The ClinicalTrials.gov registry entry for NCT00002259 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Lederle Laboratories, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mitoxantrone hydrochloride is the first listed.

NCT00002259 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00002259 about?

NCT00002259 is a clinical study titled "Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma". To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.

What is the current status of trial NCT00002259?

This trial is currently completed. It is a Phase 2 study.

What interventions are being tested in trial NCT00002259?

The interventions under investigation include: Mitoxantrone hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00002259?

This trial is sponsored by Lederle Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.